A prospective Chinese study reported striking responses in locally advanced nasopharyngeal carcinoma when camrelizumab was added to induction chemotherapy before concurrent chemoradiotherapy. Investigators observed high complete response rates with a favorable safety profile. The sequencing finding strengthens a growing argument that front-loading immunotherapy may improve depth of response in head and neck oncology—an area where standard regimens have historically delivered variable outcomes.